Loading
When ibrutinib-type drugs stop working in CLL, the usual reason is a mutation at the exact spot the drug binds (BTK C481S) or just downstream (PLCG2); when venetoclax fails, a BCL2 G101V mutation loosens its grip. Each can be seen in blood months before the disease visibly relapses, and each points to a different next drug.
What is measured: acquired mutations in BTK, PLCG2 and BCL2 that explain progression on targeted therapy. How: sensitive next-generation sequencing or digital PCR on peripheral blood CLL cells (or cell-free DNA) at progression or on surveillance. BTK C481S accounts for over 80 percent of resistance to the covalent inhibitors (ibrutinib, acalabrutinib, zanubrutinib), with C481R/F/Y variants; T474I and L528W arise on pirtobrutinib and zanubrutinib and, being kinase-dead, also resist pirtobrutinib; PLCG2 gain-of-function mutations (R665W, L845F, S707Y) act downstream; BCL2 G101V (and D103Y and others) appears in about half of venetoclax relapses, often subclonal and up to two years before clinical progression, but not typically in patients treated for a fixed duration and retreated after a gap. What a result changes: covalent BTK inhibitor failure with C481S leads to pirtobrutinib (BRUIN) or a venetoclax-based regimen; kinase-dead mutations lead to venetoclax, BTK degraders in trials, CAR-T (lisocabtagene maraleucel is approved for CLL) or bispecific antibodies; a BCL2 mutation leads to a BTK inhibitor or trials and makes venetoclax retreatment less reliable; a rapidly growing node is biopsied for Richter transformation before any switch. Where it matters: CLL, relapsed CLL, mantle cell lymphoma and Waldenström's.
In plain words · The signalling enzyme that B-cell cancers use to survive. Blocking it turned chronic lymphocytic leukaemia into a disease controlled by a daily pill.
Showing the target this term concerns: BTK (Bruton tyrosine kinase).
Shares PLCG2, Pirtobrutinib, Zanubrutinib, B-cell receptor / BTK signalling (to NF-κB).
Shares Intrinsic apoptosis (BCL-2 family), Resistance routes: how a blocked pathway comes back, BCL-2, Next-generation sequencing (NGS).
Shares Pirtobrutinib, Zanubrutinib, Acalabrutinib, Ibrutinib.
Shares Pirtobrutinib, Zanubrutinib, Acalabrutinib, Ibrutinib.
Shares Zanubrutinib, Acalabrutinib, BTK (Bruton tyrosine kinase), Ibrutinib.
Shares Zanubrutinib, B-cell receptor / BTK signalling (to NF-κB), Acalabrutinib, BTK (Bruton tyrosine kinase).
Shares Acalabrutinib, Relapsed or refractory chronic lymphocytic leukaemia, BTK (Bruton tyrosine kinase), Ibrutinib.
Shares Acalabrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Ibrutinib, Chronic lymphocytic leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/